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CASE REPORT
Adenocarcinoma arising from a foregut cyst 
of the diaphragm: importance of multimodality 
treatment: a case report
Jozsef Furak1*†, Anna Rieth2†, Aurel Ottlakan1, Tibor Nemeth1, Laszlo Torday3, Laszlo Tiszlavicz4 
and Gyorgy Lazar1
Abstract 
Background: Benign foregut cysts usually develop in the thorax most of all in the mediastinum. Rare cases involving 
various abdominal organs, such as liver, stomach or pancreas have been previously published, mostly occurring in the 
retroperitoneum.
Case presentation: We herein present an adenocarcinoma of a foregut cyst involving the left side of the diaphragm, 
left lower lobe of the lung, and left lobe of the liver, successfully removed through multivisceral resection. In between 
drug holidays, postoperative oncological treatment has been ongoing for nearly 4 years. In terms of chemotherapy, 
FOLFOX 4 regime, capacitabine monotherapy and later on next generation sequencing has been attempted, 
although the patient refused the later treatment option. Despite multimodality (combined surgical and oncological) 
treatment, local- and later on loco-regional recurrence has been detected on follow-up staging, influencing further 
chemotherapy regime. Taking both the fairly unknown type of the tumor and uncertain response rate to oncologi-
cal therapy into account, prolonged tumor pace with fairly stable general patient state was reached throughout the 
course of the disease.
Conclusion: Through surgical tumor resection, and postoperative chemotherapy the patient managed to maintain 
an acceptable quality of life without major symptoms during ongoing treatment. During our own case, with multiple 
organ involvement, multivisceral resection, with multimodality treatment had considerable effect in prolonging the 
lifespan of the patient.
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Background
Until recently, about 200 primary diaphragm tumors 
have been reported worldwide [1]. Primary benign 
lesions include mesothlial cysts, mostly occurring in 
children, and tumors arising from bronchogenic cysts 
[2]. The most frequent benign tumors of the diaphragm 
include lipomas, with the first case reported in 1886, 
by Clark [3]. However, benign lesions, such as lipomas 
may in some percentage transform into liposarcomas, 
thus resection of these seemingly harmless lesions is in 
most cases mandatory [4]. Malignant diaphragm lesions 
include rhabdomyosarcomas, usually with poor progno-
sis, although patients often benefit from the combination 
of surgical resection, chemotherapy and postoperative 
irradiation [5]. Leiomyosarcomas occur relatively rare at 
the site of the diaphragm, leaving only surgical resection 
as a feasible treatment option [6]. Secondary malignant 
lesions of the diaphragm often occur due to neighbouring 
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malignant tumors, most frequently lung cancer, meso-
thelioma, or thymomas [7]. Adenocarcinoma of a fore-
gut cyst (AFC) to our knowledge has only scarcely been 
described in literature. Tumors, such as AFC, require 
special treatment, and handling, due to the lack of 
information on tumor behaviour and available treat-
ment options. Our own case not only deals with a pre-
viously undescribed malignancy, but due to multivisceral 
involvement, also resulted in personalized, multimodal-
ity, combined oncological and surgical treatment (mul-
tivisceral resection), leading to prolonged lifespan and 
acceptable quality of life for the patient.
Case presentation
A 66-year-old woman presented at our Department with 
chest-, and abdominal pain. During work-up, contrast 
enhanced chest- and abdominal computed tomogra-
phy (CT) verified a large mass (10 × 6 × 5.5 cm) located 
in the left diaphragm, suggesting infiltration of the fun-
dus of the stomach and the left lobe of the liver. An exo-
phytic mass measuring 1.5  cm in diameter was seen at 
the posterior wall of the stomach, with low amount of 
calcification. A 13 mm large lymphnode, on the left side, 
posterior to the crus of the diaphragm was visible, other-
wise there were no pathologically enlarged lymphnodes 
in the abdomen, or the pelvis (Figs. 1, 2). The patient had 
no history of malignancies, and at initial presentation no 
distant metastases were confirmed on imaging. Left sided 
atelectasis and pleural fluid were also described on chest 
CT. Gastroscopy was negative. Ultrasound guided fine 
needle biopsy of the mass suggested a malignancy con-
sisting of epithelial cells. On the basis of these findings, 
primary surgical approach was indicated in concordance 
with our tumor board.
After video-assisted thoracic surgery (VATS) explora-
tion excluded pleural dissemination, a left sided postero-
lateral thoracotomy was performed in the 9th intercostal 
space. The tumor was located in the left diaphragm with 
infiltration of the left lower lobe of the lung and left lobe 
of the liver. Regarding pulmonary involvment, the lesion 
was situated at the base of the left lung, in close proxim-
ity to the pericardium, with medial border reaching the 
diaphragmatic crura and lateral border on the thoracic 
wall. There were no potential cysts, or pseudocysts iden-
tified during the surgical procedure.
Multivisceral resection was carried out, involving 
resection- and reconstruction of the left diaphragm 
(Gore-tex® Dualmesh®), wedge resection of the left 
lower lung lobe and resection of the left liver lobe. 
The tumor did not involve the stomach. Postoperative 
period was uneventful, and the patient was discharged 
after 7 days. Histology revealed the following findings: 
(1) resected lung specimen (wedge-resection): BOOP 
(Bronchiolitis Obliterans Organizing Pneumonia)-like 
picture: intraalveolar, organizing fibrotic tissue, with 
significant interstitial chronic cell inflammation. Sec-
ondary vascular pulmonary hypertension, without 
presence of malignancy in the specimen. (2) Perito-
neum: fibrotic pseudocysts without inner epithelial lin-
ing, PAS-AK dying suggested the presence of mucus, 
rich in acidic mucosacharids. There was no detect-
able vital tumor tissue in the sample. The presence of 
necrotic metastases was suggested. (3) Resected dia-
phragm: Previously mentioned pseudocysts detected 
besides striated muscle-, and liver tissue, with 
extended necrosis, accumulated neutrophil granulo-
cyts, and focal vital tumor tissue. A well-moderately 
Fig. 1 Preoperative computed tomography (CT) showing the lesion 
on the left diaphragm (red arrow)
Fig. 2 Preoperative cross-sectional CT image of the tumor (red 
arrow)
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differentiated adenocarcinoma with a papillary pattern 
was confirmed, with high amount of polysacharids and 
mucin. Immune-phenotyping showed focal positivity 
for CK7, MucAc (3 +), Ki67 (3 +), p53 do-7 clone (3 +) 
and CDX2 and negative reaction for TTF1 (Transcrip-
tion Termination Factor 1), CK20, Napsin A, Thyreo-
globulin, and Surfactant protein immune acid (Figs.  3, 
4). On the basis of the above findings, a well-differenti-
ated, low-grade adenocarcinoma arising from a foregut 
cyst was confirmed. Surgical resection margins proved 
to be clear, resulting in complete, R0 resection.
After the procedure, no postoperative chemother-
apy was initiated due to both clear surgical resection 
margins and strong patient preference. Follow-up CT 
one month after surgery showed a tumor-free state 
(Fig. 5).
Six months after surgery, during regular follow-up, 
novel hepatic and splenic lesions have been detected 
on abdominal CT. After a further two months, addi-
tional disease progression was confirmed involving 
both hepatic and splenic metastases (Fig.  6). PET-CT 
(positron emission tomography-computed tomography) 
showed distant metastases within the left liver lobe and 
left supraclavicular lymph nodes. A splenic lesion has 
Fig. 3 Typical acino-papillary pattern of 
well-moderately differentiated adenocarcinoma with reactive 
granulocytes (Hematoxylin–eosin staining, 10×)
Fig. 4 The nuclear positivity of proliferation marker (braunish) 
affecting 25% of tumor cells (Immunohistochemistry, Ki-67, 40× )
Fig. 5 Postoperative CT, 1 month after surgery, showing tumor-free 
state
Fig. 6 Postoperative CT showing loco-regional failure at the site of 
the spleen (red arrow)
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been described involving the gastric wall at the lesser and 
greater curvature with neighbouring lymphnode enlarge-
ment. As the next treatment approach, palliative FOL-
FOX4 chemotherapy has been initiated. After 5 cycles 
of treatment (2.5  months) due to the lack of any physi-
cal symptoms and stable disease confirmed on follow-up 
CT, the patient refused further oncological treatment, 
thus a drug holiday was initiated with regular follow-ups 
and tumor staging. After 19 months without any chemo-
therapy (drug holiday), the patient started complaining of 
worsening abdominal pain and cramps. Urgent CT con-
firmed disease progression, hence capecitabine mono-
therapy was started. After initiation of this treatment, 
symptoms rapidly improved. Three cycles (2  months) 
were delivered, and new imaging (CT) was carried out, 
confirming further, slight increase concerning the splenic 
lesion. We suggested continuing chemotherapy with an 
enhanced regimen, the patient however refused to con-
tinue treatment on the grounds of lacking symptoms. 
After a 7.5  month drug free period, follow up CT con-
firmed considerable progression of splenic metastases. 
The patient expressed clear preference for oral therapy, 
thus capecitabine was reinitiated (Figs. 7, 8). After finish-
ing 7 new cycles (5 months), progression was once again 
detected on imaging. Afterwards, the patient was suc-
cesfully convinced to accept intravenous chemotherapy, 
so treatment regimen could be enhanced to FOLFOX4. 
With this regimen, stable disease was achieved after 6 
cycles (3  months) although treatment was once again 
discontinued due to patient request. Considering the 
fact that on one occasion capecitabine improved tumor 
related symptoms and both capecitabine and FOLFOX4 
stopped further disease progression, both regimens 
seemed to be effective in the management of the dis-
ease. Throughout the oncological management, the best 
presumed therapy was taken into consideration, in con-
cordance with patient preference, and taking the course 
of the disease with best achievable response into account 
in maintaining a relatively stable patient condition and 
tumor stage. Facing a rare occurring tumor without 
established oncological treatment options, and patient 
rejection of cytotoxic chemotherapy, in order to identify 
potentially targetable driver mutations, next generation 
seqencing (NGS) was requested as a subsequent step. 
The FDA (Food and Drug Administration) approved FMI 
CDx (FoundationOne® Companion Diagnostic) assay 
was applied which analysed 315 genes as well as introns 
of 28 genes involved in rearrangements. The follow-
ing relevant genomic alterations were identified: ATM 
E522fs*43 mutation, KRAS Q61K mutation, PBRM1 
rearrangement intron 10. The loss of functional ATM 
results in a defective DNA damage response and homol-
ogous recombination-mediated DNA repair, and may 
predict sensitivity to PARP inhibitors such as olaparib, 
rucaparib, and niraparib. Preclinical evidence suggests 
that KRAS activation may predict sensitivity to MEK 
inhibitors, such as trametinib and cobimetinib. There are 
no targeted therapies available to address genomic altera-
tions in PBRM1. On the basis of these findings and with 
confirmed disease progression, the application of one 
of the PARP inhibitors was intended, however, despite 
detailed description of potential health benefits, the 
patient refused to accept recommended treatment. After 
39  days the patient was eventually admitted to the 1st 
Fig. 7 CT-sagittal view of recurrent tumor at the site of the spleen, 
3 year after surgery (red arrow)
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Department of Medicine with acute hematemesis. Con-
troll gastroscopy confirmed a large tumorous infiltration 
inside the fornix of the stomach without acute bleeding 
at the time of intervention. However one day after admis-
sion, general patient condition showed rapid progres-
sion with cardiac- and respiratory insufficiency and the 
patient passed away on the following day [nearly 4 years 
(1389 days) after surgery] (Fig. 9).
Discussion and conclusions
Foregut cysts (FC) are congenital developmental abnor-
malities of the foregut occurring during embryogen-
esis. Although FCs are most frequently found in the 
mediastinum, due to their assumed origin from bron-
chial branches, in some cases they can also descend to 
the abdominal cavity, leading to the development of an 
abdominal FC. Malignant transformation of FCs are 
extremely rare, however cases have been reported on 
transformed cysts in the retroperitoneum and in organs 
of the abdominal cavity [8].
Curative treatment of such multiple organ involving 
malignancies may well be surgery, or palliative treatment 
(bypass, palliative chemotherapy) at the most in unre-
sectable cases. Our case involved multiple resection of 
intra-abdominal organs (diaphragm, lung, liver), followed 
by adjuvant chemotherapy, with anticipated prolonged 
survival of the patient, which has been confirmed dur-
ing follow-up (despite regional recurrence), since the 
patient maintained acceptable quality of life throughout 
a relatively long time period (1389  days after surgery). 
In cases such as ours, the pivotal role of multimodality 
treatment should be highly emphasized. In cases such 
as AFC, the lack of previous treatment experience and 
unknown response to oncological treatment may ham-
per successful therapy. The application of personalized 
treatment strategy and targeted therapy could lead to 
improved quality of life and survival. It is well described 
that cancer development is in close connection with the 
genome [9]. The use of various sequencing modalities 
has enabled us to identify genetic aberrations in numer-
ous tumors. Tumor heterogeneity plays a pivotal role in 
applying targeted therapies, due to the fact that it is not 
only found among different patients, but also within the 
same patient at various sites (intrapatient heterogene-
ity), or even within the same tumor, at different loca-
tions (intratumor heterogeneity) [9]. Next generation 
sequencing results in a highly specific diagnosis based 
on genotype. During NGS, cancer specimens are ana-
lysed for fundamental alterations, such as base substitu-
tions, insertions and deletions, copy number alteration, 
and rearrangements [10]. According to a prospective, 
multi-center study, among 86 cancer patients (colorectal, 
breast, ovarian) undergoing genetic profiling, a molecu-
lar target was identified in 98%. Eighteen patients (27%), 
received genomically guided treatment (GGT) and suc-
cessfully reached progression-free survival, thus GGT 
was found beneficial and feasible in these cases [11]. 
In a study conducted by Hasselgren et  al., involving 42 
patients undergoing multivisceral resections, no sig-
nificant correlation between postopertaive morbidity, 
number of resected organs and number of anastomoses 
was noted, however a tendency in postoperative com-
plications became apparent in cases where more than 4 
organs were resected [12]. In similar operable cases, even 
with potentially increased morbidity, multivisceral resec-
tion seems to be the only feasible solution [12]. Treat-
ment options of malignant lesions arising from FCs have 
previously been described in literature, although mostly 
with palliative management and the lack of appropriate 
follow-up, or survival data [13]. Multivisceral resections 
involving hepatectomy, or pancreatectomy combined 
with at least one other organ resection carry a 7% post-
operative mortality rate with 59% complication rate [12], 
however postoperative recovery was uneventful in our 
case, without any perioperative morbidity. Nonetheless, 
Fig. 8 CT-frontal view of recurrent tumor at the site of the spleen, 
3 years after surgery (red arrow)
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according to a retrospective analysis by McKay, et al. on 
the postoperative outcomes of multivisceral resections, 
disease free survival after combined hepatic and pan-
creatic resections was 10  months and after multiorgan 
resections involving hepatic-, or pancreatic resection, 
3  year overall survival was 79% [12]. Based on our own 
case,—despite loco-regional failure at 6  months-, onco-
logical treatment through postoperative chemotherapy 
successfully resulted in an acceptable quality of life, in 
spite of distant metastases occuring later on. The nearly 
4 year (1389 days) survival rate, along with the previously 
mentioned tumor recurrence shows, that due to its low 
grade malignant features, the pace of tumor advance-
ment was still moderate, resulting in a prolonged course 
of the disease. Taking aspects of tumor development into 
consideration, multimodality treatment through aggres-
sive surgical resection and postoperative chemotherapy 
was deemed a relatively successful approach.
Limitations
There are some limitations to the above discussed case.
1 Our case included a little known, highly complex 
malignant lesion, without previous data of defini-
tive pre-, or postoperative oncological treatment. 
After histology confirmed tumor origin, postopera-
tive treatment was initiated based on similar foregut 
derived malignancies, since no previous adjuvant 
treatment plan served as a model, on which our own 
treatment strategy could have been constructed.
2 Since scarce information on the malignant poten-
tial of the lesion, it was extremely difficult to predict 
treatment response and outcome.
3 Authors agree on the fact, that based on a single case, 
no far-reaching conclusions can be drawn from the 
above mentioned condition in terms of treatment 
algorithm and life expectancy. Careful patient selec-
tion and thorough preoperative work-up certainly 
may facilitate successful surgical/oncological therapy.
4 With the detailed discussion and treatment recom-
mendation through the case, the authors hope to 
have made an effort to better understand foregut 
derived malignancies and added valuable informa-
tion on overall treatment planning, contributing to 
improved survival rates.
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Fig. 9 Treatment algorithm of primary adenocarcinoma of the diaphragm
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